Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3347 |
Name | osteosarcoma |
Definition | A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). |
Source | DiseaseOntology.org |
Alt Ids | DOID:183 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer bone sarcoma osteosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 R280M | Nutlin-3a | osteosarcoma | resistant | detail... |
TP53 I232S | Nutlin-3a | osteosarcoma | resistant | detail... |
TP53 E258Q | Nutlin-3a | osteosarcoma | resistant | detail... |
TP53 P177T | Nutlin-3a | osteosarcoma | resistant | detail... |
RB1 wild-type TP53 mut | R547 | osteosarcoma | sensitive | detail... |
TP53 wild-type | CPUY201112 | osteosarcoma | sensitive | detail... |
TP53 loss | CPUY201112 | osteosarcoma | decreased response | detail... |
RB1 mutant | VCN-01 | osteosarcoma | sensitive | detail... |
TP53 wild-type | KRT-232 | osteosarcoma | sensitive | detail... |
TP53 wild-type | KRT-232 + Radiotherapy | osteosarcoma | sensitive | detail... |
TP53 mutant | N/A | osteosarcoma | not applicable | detail... |
PTEN loss | MK2206 | osteosarcoma | sensitive | detail... |
PTEN loss | Sirolimus | osteosarcoma | sensitive | detail... |
BRAF G469V | Trametinib | osteosarcoma | no benefit | detail... |
MLH1 negative | Pembrolizumab | osteosarcoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | osteosarcoma | sensitive | detail... |
RAD51C T132R | Olaparib | osteosarcoma | sensitive | detail... |
RAD51C K131I | Olaparib | osteosarcoma | sensitive | detail... |
RAD51C G130R | Olaparib | osteosarcoma | sensitive | detail... |
RAD51C R168G | Olaparib | osteosarcoma | sensitive | detail... |
TSC2 mutant | Temsirolimus | osteosarcoma | no benefit | detail... |
TSC2 mutant | Irinotecan + Temozolomide + Temsirolimus | osteosarcoma | no benefit | detail... |
EML4 - ALK | Alectinib | osteosarcoma | predicted - sensitive | detail... |
EML4 - ALK | Lorlatinib | osteosarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00902044 | Phase I | Fludarabine Cyclophosphamide HER2 sensitized T-cells | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT01241162 | Phase I | Decitabine | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | Completed | USA | 0 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01759303 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | Terminated | USA | 0 |
NCT01956669 | Phase II | Pazopanib | Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | Completed | USA | SVK | HUN | FRA | ESP | CZE | CAN | 0 |
NCT02013336 | Phase I | Cyclophosphamide + Liposomal irinotecan | Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors | Unknown status | USA | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Completed | USA | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Completed | USA | 0 | |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Completed | USA | 0 |
NCT02389244 | Phase II | Regorafenib | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) | Active, not recruiting | FRA | 0 |
NCT02406781 | Phase II | Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) | Unknown status | FRA | 0 |
NCT02432274 | Phase Ib/II | Etoposide Lenvatinib Cyclophosphamide | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02470091 | Phase II | Denosumab | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | Completed | USA | CAN | 1 |
NCT02487979 | Phase II | Glembatumumab vedotin | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | Completed | USA | CAN | 1 |
NCT02517918 | Phase I | Cyclophosphamide + Methotrexate + Sirolimus + Zoledronic acid | Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma a (METZOLIMOS) | Completed | FRA | 0 |
NCT02644460 | Phase I | Abemaciclib | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | Completed | USA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Completed | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT02982941 | Phase I | MGA271 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | Completed | USA | 0 |
NCT03006848 | Phase II | Avelumab | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | Completed | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03190174 | Phase Ib/II | Nab-rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Completed | USA | 0 |
NCT03242382 | Phase II | Palbociclib | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) | Recruiting | ESP | 0 |
NCT03277924 | Phase Ib/II | Nivolumab + Sunitinib | Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc) | Completed | ITA | GBR | ESP | 0 |
NCT03282344 | Phase II | Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03320330 | Phase Ib/II | Pepinemab | VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | Completed | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03449108 | Phase II | Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Iovance Alliance: LN-145 Across Multiple Tumor Types | Active, not recruiting | USA | 0 |
NCT03458728 | Phase Ib/II | Copanlisib | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Terminated | USA | 0 |
NCT03628209 | Phase Ib/II | Azacitidine + Nivolumab | Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma | Active, not recruiting | USA | 0 |
NCT03635632 | Phase I | C7R-GD2.CAR-T cells Cyclophosphamide + Fludarabine | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | Active, not recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Completed | USA | 0 |
NCT03811886 | Phase Ib/II | Natalizumab | Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma | Recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03900793 | Phase I | Losartan + Sunitinib | Losartan + Sunitinib in Treatment of Osteosarcoma | Recruiting | USA | 0 |
NCT03960177 | Phase I | Glucarpidase | Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma | Active, not recruiting | USA | 0 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT04055220 | FDA approved | Regorafenib | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA) | Recruiting | FRA | 0 |
NCT04154189 | Phase II | Etoposide + Ifosfamide Etoposide + Ifosfamide + Lenvatinib | A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | Completed | USA | SWE | NZL | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT04183062 | Phase II | BIO-11006 + Docetaxel + Gemcitabine | BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases | Withdrawn | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04417062 | Phase II | Ceralasertib + Olaparib | Olaparib With Ceralasertib in Recurrent Osteosarcoma | Recruiting | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04544995 | Phase I | Dostarlimab-gxly + Niraparib | Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors | Recruiting | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
NCT04595994 | Phase I | Selinexor | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma | Recruiting | ESP | 0 |
NCT04616560 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma | Suspended | USA | 0 |
NCT04661852 | Phase I | Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan | Cabozantinib With Topotecan-Cyclophosphamide | Completed | USA | 0 |
NCT04668300 | Phase II | Durvalumab + Oleclumab | Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa) | Recruiting | USA | 0 |
NCT04698785 | Phase II | Regorafenib | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients (REGOMAIN) | Recruiting | FRA | 0 |
NCT04751383 | Phase I | Dinutuximab + Hu5F9-G4 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | Terminated | USA | CAN | 0 |
NCT04758000 | Phase II | Metformin | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse (Metform-Bone) | Recruiting | ITA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04803877 | Phase II | Nivolumab + Regorafenib | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | Active, not recruiting | USA | 0 |
NCT04833582 | Phase Ib/II | Gemcitabine + ZN-c3 | A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma | Active, not recruiting | USA | FRA | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04870944 | Phase Ib/II | CBL0137 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Recruiting | USA | AUS | 0 |
NCT04897880 | Phase II | Panobinostat | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH) | Terminated | USA | NZL | AUS | 0 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT04974008 | Phase II | ADXS31-164 | Osteosarcoma Maintenance Therapy With OST31-164 (OST-164-01) | Completed | USA | 0 |
NCT05019703 | Phase II | Atezolizumab + Cabozantinib | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | Recruiting | USA | 0 |
NCT05093322 | Phase Ib/II | Gemcitabine + Surufatinib | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05131386 | Phase II | Dexamethasone + Trabectedin | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) | Recruiting | ESP | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05182164 | Phase II | Cabozantinib + Pembrolizumab | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) | Recruiting | FRA | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |
NCT05302921 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | Active, not recruiting | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT05395741 | Phase Ib/II | Regorafenib | Regorafenib in Patients With Refractory Primary Bone Tumors (Regbone) | Recruiting | POL | 0 |
NCT05588648 | Phase Ib/II | Vactosertib | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | Recruiting | USA | 1 |
NCT05621668 | Phase I | AttIL12 T-cells + Cyclophosphamide | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma | Recruiting | USA | 0 |
NCT05691478 | Phase II | Cisplatin + Doxorubicin + Methotrexate Doxorubicin + Methotrexate Cabozantinib Cabozantinib + Cisplatin + Doxorubicin + Methotrexate Cabozantinib + Doxorubicin + Methotrexate | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Suspended | USA | 0 |
NCT05703854 | Phase Ib/II | CAR.70/IL15-transduced CB-NK cells Cyclophosphamide + Fludarabine | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma | Recruiting | USA | 0 |
NCT05726383 | Phase II | Mistletoe extract | Immunotherapy for Recurrent Osteogenic Sarcoma | Recruiting | USA | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT06156410 | Phase I | Cabozantinib + Ifosfamide | Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma | Recruiting | USA | 0 |
NCT06341712 | Phase II | Cabozantinib | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma (CabOSTar) | Recruiting | USA | SWE | POL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 0 |
NCT06474676 | Phase I | AttIL12 T-cells Cyclophosphamide | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Not yet recruiting | USA | 0 |
NCT06492954 | Phase I | Atezolizumab | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma (AflacST2301) | Recruiting | USA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG | 1 |
NCT06541262 | Phase Ib/II | Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide | Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |